secwatch.observer — SEC 8-K summary
======================================

Issuer:     Bluejay Diagnostics, Inc. (BJDX)
CIK:        0001704287
Form:       8-K
Filed at:   2026-08-13T11:56:27+00:00
Accession:  0001213900-26-088701
Event type: other_material
Sentiment:  positive
Materiality: 0.70
Item codes: 7.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Bluejay completes SYMON-II enrollment of 750 patients; cash $9.6M, runway to Q2 2027
--------------------------------------------------------------------------------

- Completed targeted enrollment of 750 patients in SYMON-II pivotal study for Symphony IL-6 test.
- Cash and equivalents $9.6M at June 30, 2026 vs $5.2M at Dec 31, 2025; net proceeds $7.6M from June 2026 private placement.
- Signed US manufacturing contract to mitigate supply-chain risk; advancing toward FDA 510(k) submission.
- Cash estimated to fund operations through Q2 2027.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1704287/000121390026088701/0001213900-26-088701-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1704287/000121390026088701/ea0301888-8k_bluejay.htm
  HTML page:      https://secwatch.observer/filing/0001213900-26-088701

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer